Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck.

Trial Profile

Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Head and neck cancer; Precancerous conditions
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top